The Pill That Wants to Give Your Dog More Years

For most of recorded history, the deal was simple and non-negotiable: you would outlive your dog. You would get, if you were lucky, somewhere between eight and fifteen years. Then the grey muzzle, the slower pace, the dimming eyes — and the decision that love sometimes requires. This has been the fixed arithmetic of keeping a dog. Until, possibly, now.

In February 2025, the US Food and Drug Administration's Center for Veterinary Medicine granted Loyal — a San Francisco-based longevity biotech — a Reasonable Expectation of Effectiveness (RTEC) determination for its large-breed dog ageing drug LOY-002. It was, the company said, the first time a drug had received that determination for the indication of extending healthy lifespan in dogs. In plain terms: a US regulator had looked at the available data and said it was plausible — not proven, but plausible — that this drug could add years to a large dog's life.

What LOY-002 actually is

LOY-002 is a small-molecule drug that targets IGF-1 — insulin-like growth factor 1 — the hormone pathway long associated with the inverse relationship between body size and lifespan in dogs. Large dogs have markedly higher IGF-1 levels than small dogs, and they age dramatically faster: a Great Dane can be considered geriatric at five years; a Chihuahua at twelve. The relationship between IGF-1, body size, and lifespan is one of the most robust associations in comparative ageing research.

Loyal's hypothesis is that by modulating IGF-1 signalling in large breeds, LOY-002 can slow the biological processes that drive their accelerated ageing. The drug is intended for daily oral use in large and giant breeds, administered throughout their adult life. The RTEC determination was granted on the basis of the proposed mechanism of action and preliminary safety and efficacy data — it is not the same as full regulatory approval, and it does not mean the drug has been shown in a large clinical trial to extend dog lifespan. That trial is ongoing.

The science behind the hypothesis

The IGF-1 / body size / lifespan story in dogs is unusually well-supported. Studies mapping the genetics of body size across dog breeds have repeatedly identified variants near the IGF1 gene as the dominant determinant of adult weight. And the epidemiological relationship between size and longevity in dogs is stark: the Rottweiler lives on average ten years; the Border Terrier, fourteen. The difference maps closely onto IGF-1 levels.

The broader biological context makes this plausible. In model organisms — C. elegans nematodes, Drosophila, mice — mutations that reduce IGF-1 / insulin signalling consistently extend lifespan, often substantially. In humans, rare mutations in the IGF-1 receptor are associated with reduced cancer rates and altered ageing trajectories in some populations. The mechanistic case for IGF-1 as a longevity lever has been built over decades of geroscience research.

The Dog Aging Project: a parallel endeavour

Loyal is not the only serious scientific effort training its sights on dog longevity. The Dog Aging Project — a large-scale, NIH-funded collaborative study led by researchers at the University of Washington and Texas A&M — is running the TRIAD trial: a randomised controlled trial of rapamycin, an mTOR inhibitor, in middle-aged dogs. Rapamycin has extended lifespan in every model organism it has been tested in, including mice — one of the strongest longevity-drug findings in geroscience.

The Dog Aging Project is also assembling what will be the largest longitudinal study of ageing in any species — tens of thousands of dogs enrolled, with data on health, environment, microbiome, genome, and lifespan tracked across years. Dogs, the researchers argue, are not just beneficiaries of longevity research; they are ideal model organisms for it. They share our environment, eat our food, experience our pollutants, and develop many of the same age-related diseases — cancer, dementia, arthritis, cardiovascular disease — that humans do.

Loyal's LOY-003: the cognitive angle

In parallel with LOY-002, Loyal is developing LOY-003, targeting canine cognitive dysfunction syndrome (CCDS) — the dog equivalent of dementia, which affects a significant proportion of older dogs. The company has described LOY-003 as addressing the cognitive component of ageing separately from the lifespan mechanism targeted by LOY-002. Both programmes reflect a broader thesis: that ageing itself, not individual diseases, is the appropriate therapeutic target.

The honest caveats

All of this — the RTEC determination, the rapamycin results in mice, the IGF-1 biology — is genuinely exciting. It is also genuinely preliminary. The RTEC determination is not marketing approval. It is a conditional regulatory signal, granted because the mechanism is biologically plausible and initial safety data are acceptable. The large clinical trial that would actually demonstrate extended healthy lifespan in dogs had not, as of early 2026, published its results. The bar for "works in a clinical trial with actual dogs" is considerably higher than "mechanism is plausible."

Rapamycin has extended lifespan in mice. It has not been shown in a completed, published, peer-reviewed RCT to extend lifespan in dogs. It is an immunosuppressant with known side effects. Its long-term safety profile in healthy dogs is still being established. The Dog Aging Project's TRIAD trial will provide important answers, but the results are pending.

The deeper significance

Whatever the eventual clinical results, the longevity research moment in canine science represents something more than a drug pipeline. It represents a shift in how we think about the dog lifespan: not as a fixed, natural fact to be accepted, but as a biological variable that medicine might extend. That shift has implications for how veterinary care is practised — the growing field of veterinary geriatrics, the rise of senior wellness screening — and for what dog owners reasonably expect.

It also has implications for the research itself. The Dog Aging Project's argument — that dogs and humans age together, that studying dog ageing advances human longevity science — is a compelling case for pets as research partners rather than mere research subjects. The arithmetic of the deal may be changing. But the reason it matters — the fifteen years, the grey muzzle, the deal that was never long enough — has not changed at all.